Thalidomide Combined with Second-line Regimen in Relapsed or Refractory ITP：a Observation Study

doi:10.3969/j.issn.1671-2587.2023.01.022

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2023, Vol. 25 ›› Issue (1): 133-136.DOI: 10.3969/j.issn.1671-2587.2023.01.022

Previous Articles Next Articles

Thalidomide Combined with Second-line Regimen in Relapsed or Refractory ITP：a Observation Study

GE Hong-Feng, LI Shu-e, CHU Hai-liang, et al

Department of Hematology, Bozhou Hospital Affiliated to Anhui Medical University,Bozhou 236800

Received:2022-07-29 Published:2023-02-20

Abstract

Abstract: Objective To investigate the efficacy of thalidomide combined with a second-line regimen in the treatment of patients with relapsed and refractory immune thrombocytopenic purpura (ITP) and its effect on Th1/Th2 cytokines. Methods From January 2016 to March 2021, 86 patients with relapsed and refractory ITP admitted to Bozhou people's Hospital were enrolled and randomly divided into observation group and control group, with 43 patients in each group. The control group was treated with dexamethasone and rituximab, and the observation group was given thalidomide orally on top of the control group regimen. The curative effect was evaluated at 12 weeks of treatment in both groups. The changes in bleeding score, platelet count (PLT), Th1 cytokine [tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and interleukin-2 (IL-2)] and Th2 cytokine [interleukin-4 (IL-4) and interleukin-10 (IL-10)] levels were compared before treatment and at 12 weeks of treatment. Results The total effective rate of treatment in the observation group was 93.02%, which was significantly higher than that in the control group (72.09%) (P<0.05). At 12 weeks of treatment, the bleeding scores of both groups were lower than before treatment (P<0.05), and the bleeding scores of the observation group were significantly lower than those of the control group (P<0.001); the PLT count of the observation group was significantly higher than that of the control group (P<0.001); the serum TNF-α, IFN-γ and IL-2 levels of both groups were significantly lower than those before treatment (P<0.05), and the observation group was significantly lower than that of the control group (P<0.001); serum IL-4 and IL-10 levels were significantly higher than before treatment (P<0.05), and the observation group was significantly higher than the control group (P<0.001). Conclusion Thalidomide combined with the second-line regimen has a significant clinical effect in the treatment of patients with relapsed and refractory ITP, which can regulate the levels of Th1/Th2 cytokines.

Key words: Thalidomide, Dexamethasone, Rituximab, Relapsed and refractory immune thrombocytopenic purpura, Curative effect, Th1/Th2 cytokine

CLC Number:

R558

GE Hong-Feng, LI Shu-e, CHU Hai-liang, et al. Thalidomide Combined with Second-line Regimen in Relapsed or Refractory ITP：a Observation Study[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(1): 133-136.

References

[1] ROOSE E,SCHELPE A,TELLIER E,et al.Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura[J].Blood,2020,136(3): 353-361.
[2] SAKAI K.Long-term cognitive impairments following recovery in the patients with immune- mediated thrombotic thrombocytopenic purpura[J].Br J Haematol,2020,191(5): 671-672.
[3] 黄月婷,刘晓帆,付荣凤,等.艾曲泊帕治疗成人原发免疫性血小板减少症的临床分析[J].临床血液学杂志,2019,32(1): 16-19, 23.
[4] 田勇,高鹏,韩梅,等.干扰素-γ和白细胞介素-22联合检测在原发性免疫性血小板减少性紫癜中的临床意义[J].中国老年学杂志,2019,39(16): 4014-4015.
[5] 罗洪强,封蔚莹,周国忠.重组人血小板生成素对难治性原发性免疫性血小板减少性紫癜患者T、B淋巴细胞功能的影响.[J]中国卫生检验杂志,2019,29(17): 2089-2091.
[6] 胡学琼,宝国秀,王红霞,等.小剂量利妥昔单抗与环孢素治疗难治性原发性免疫性血小板减少症的疗效及安全性分析[J].中国药物与临床,2020,20(20): 3476-3478.
[7] 中华医学会血液学分会止血与血栓学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J].中华血液学杂志,2016,37(2): 89-93.
[8] KIMBARA S,IMAMURA Y,YAKUSHIJIN K,et al.Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report[J].Mol Clin Oncol,2021,14(2): 30.
[9] CASTELLI R,DELILLIERS GL,GIDARO A,et al.Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course[J].Clin Exp Immunol,2020,201(3): 258-265.
[10] NGUYEN TH,TRAN TT,HOANG TT,et al.Rotational thromboelastometry parameters as predicting factors for bleeding in immune thrombocytopenic purpura[J].Hematol Oncol Stem Cell Ther,2021,41(1): 27-32.
[11] 黄月婷,刘晓帆,陈云飞,等.艾曲泊帕治疗成人慢性原发免疫性血小板减少症的疗效及安全性[J].中华血液学杂志,2018,39(1): 32-36.
[12] 李举亨,成小慧,田发青.沙利度胺对于ITP患者Treg及Th17细胞亚群的影响[J].医学检验与临床,2021,32(2): 25-27.
[13] 徐丹,计成阜,陈超,等.地塞米松联合咖啡酸片治疗ITP患者对PAIgG及GPⅡb/Ⅲa抗体的影响[J].临床输血与检验,2019,21(4): 368-371.
[14] MA J, NING YN, XU M, et al.Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia. Blood, 2013. 122(12): p. 2074-2082.
[15] MENGDI XU,XIAMIN WANG,XIAOQI XU,et al.Thalidomide prevents antibody-mediated immune thrombocyto- penia in Mice.Thrombosis Research,2019,183:69-75.
[16] YANG ZG, et al.Thalidomide induce response in patients with corticosteroid-resistant or relapsed ITP by upregulating Neuropilin-1 expression. Int Immunopharmacol, 2019. 72: p. 437-444.
[17] 李赢,张小娟,张振山,等.沙利度胺联合硫酸羟氯喹对 SLE 患者白细胞及血小板计数的影响[J].航空航天医学杂志,2021,32(4):451-452.
[18] 李举亨. 沙利度胺治疗难治性原发免疫性血小板减少症1例并文献复习[J].中国现代药物应用,2018,12(12):142-143.
[19] 洪攀,傅佳萍,封蔚莹,等.艾曲泊帕联合大剂量地塞米松治疗ITP疗效分析[J].浙江临床医学,2020,22(7): 1025-1027.
[20] 黄子明,李蕊白,侯丽,等.利妥昔单抗治疗难治性原发免疫性血小板减少症的研究进展[J].中国医药导报, 2020,17(33): 38-41.
[21] 白浩成,冯静,袁忠涛,等.小剂量利妥昔单抗联合艾曲波帕治疗激素耐药性ITP的临床疗效[J].西部医学, 2020,32(1): 121-124.
[22] 马海佳,陈进,陶健,等.小剂量利妥昔单抗联合rhTPO对激素治疗无效或复发的ITP的疗效[J].江苏医药,2021,47(3): 247-250.
[23] 陶红,何正梅,史玉叶,等.重组人血小板生成素治疗老年免疫性血小板减少症的疗效与安全性分析及对Th1/Th2相关细胞因子的调控作用研究[J].中国医药科学,2021,11(2): 22-24,29.
[24] 李姜惠子,刘洋,王秀娟,等.sPD-1/sPD-L1与Th1/Th2及Th17/Treg相关细胞因子在原发免疫性血小板减少症中的研究[J].中国免疫学杂志,2019,35(4): 467-470.
[25] 于慧辉,詹延霞,季丽莉,等.原发性免疫性血小板减少症(ITP)患者CD5+B细胞对CD4+T细胞Th1/Th2型细胞因子分泌的影响[J].复旦学报(医学版),2020,47(1): 53-58.

Thalidomide Combined with Second-line Regimen in Relapsed or Refractory ITP：a Observation Study

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	TANG Que-mei, WANG Meng-ya, CHEN Xue-jun, et al. Exchange Transfusion Focusing on Blood Indexes and Adverse Reactions in Neonatal Hyperbilirubinemia [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(1): 33-37.
[2]	JIANG Chen-xia, XI Guang-jun. Effects of Batroxobin and Vasodilator on Sudden Deafness and Coagulations [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(6): 571-574.
[3]	XU Dan, JI Cheng-fu, CHEN Chao, et al. The Effect of Dexamethasone Combinated with Caffeic Acid Tablet on PAIgG and GPⅡb/Ⅲa Levels in Patients with Primary Immune Thrombocytopenia [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(4): 368-371.
[4]	CHEN Yang, CUI Ying, MENG Jun-ping, etal. An Analysis of Plasma Exchange Therapy in Patients with Crescent Type Glomerulonephritis [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2018, 20(5): 505-507.
[5]	WANG Shu-ying, ZHOU Wen-hui, LI Xin-ying, et al. Analysis of Platelet Transfusion in Liver Disease Patient [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2017, 19(4): 328-331.